Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Xu H, Magro C, Minkis K. Potential Masquerader of Malignancy: Tophaceous Gout Causing Nail Dystrophy. Dermatol Surg. 2021;47(8):1149-1150.

Singh AK, Haque M, Madarampalli B, Shi Y, Wildman BJ, Basit A, et al. Ets-2 Propagates IL-6 Trans-Signaling Mediated Osteoclast-Like Changes in Human Rheumatoid Arthritis Synovial Fibroblast. Front Immunol. 2021;12:746503.

Francini E, Montagnani F, Nuzzo PV, Gonzalez-Velez M, Alimohamed NS, Rosellini P, et al. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Netw Open. 2021;4(7):e2116536.

Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo M-, Avcin T, Bertolaccini ML, et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care Res (Hoboken). 2021;73(10):1490-1501.

Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. Nat Cancer. 2021;2(4):414-428.

Gaffney C, Liu D, Cooley V, Ma X, Angulo C, Robinson B, et al. Tumor size and genomic risk in localized prostate cancer. Urol Oncol. 2021;39(7):434.e17-434.e22.

Craney A, Petrik D, Suhku A, Qiu Y, Racine-Brzostek S, Rennert H, et al. Performance Evaluation of the MatMaCorp COVID-19 2SF Assay for the Detection of SARS-CoV-2 from Nasopharyngeal Swabs. Microbiol Spectr. 2021;9(1):e0008321.

Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):5775.

Cervera-Hernandez ME, Ikemura K, McCort ME. Cytomegalovirus skin disease in a kidney transplant patient. BMJ Case Rep. 2021;14(7).

Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.